Terms ending in 2037
Every in-force patent on Zogenix, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,603,290 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same In force · Medium confidence | Zogenix International Limited | In force | Medium confidence | |
| US 11,040,018 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same In force · Medium confidence | Zogenix International Limited | In force | Medium confidence | |
| US 11,406,606 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same In force · Medium confidence | Zogenix International Limited | In force | Medium confidence | |
| US 11,759,440 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same In force · Medium confidence | Zogenix International Limited | In force | Medium confidence | |
| US 11,786,487 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same In force · Medium confidence | Zogenix International Limited | In force | Medium confidence | |
| US 12,734,137 | Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine In force · Medium confidence | Zogenix International Limited | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.